Amylyx (AMLX) Faces a Binary Phase 3 Test. Can Avexitide Rebuild the Company?
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) has released topline results from the Phase 3 LUCIDITY trial of avexitide on August 18, 2026.
Amylyx Pharmaceuticals Inc. (AMLX)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Perceptive Advisors Joseph Edelman | 8,334,882 | $149,694,481 | +1% | 2.25% |
| 2. | Commodore Capital Egen Atkinson And Michael Kramarz | 5,650,000 | $101,474,000 | 6.04% | |
| 3. | Saturn V Capital Management Xiaoying Tian | 4,624,101 | $83,048,854 | +7% | 11.91% |
| 4. | Driehaus Capital Richard Driehaus | 3,036,970 | $54,543,981 | +2% | 0.32% |
| 5. | Adage Capital Management Phill Gross And Robert Atchinson | 1,900,000 | $34,124,000 | -47% | 0.05% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $13.51 | 3,800 | $51,338.00 | 66,900 | 2026-05-21 | Filing | |
| $12.45 | 8,100 | $100,845.00 | 63,100 | 2025-12-23 | Filing | |
| $3.70 | 10,000 | $37,005.00 | 10,000 | 2025-03-20 | Filing | |
| $2.53 | 40,000 | $101,368.00 | 233,464 | 2024-09-12 | Filing | |
| $2.13 | 50,000 | $106,590.00 | 55,000 | 2024-09-05 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $27.70 | 30,000 | $830,904.00 | 782,881 | 2026-10-05 | Filing | |
| $33.09 | 2,081 | $68,864.24 | 278,064 | 2026-09-10 | Filing | |
| $32.21 | 7,947 | $256,003.86 | 280,145 | 2026-09-10 | Filing | |
| $33.23 | 1,042 | $34,625.87 | 233,625 | 2026-09-10 | Filing | |
| $32.27 | 9,768 | $315,194.80 | 234,667 | 2026-09-10 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 10,074 | $293,153 | 0.01% | |
| 2. | 1,139 | $33,145 | 0% | |
| 3. | 721 | $20,981 | 0% | |
| 4. | 354 | $10,301 | 0% | |
| 5. | 316 | $9,196 | 0% |
News See All
Costco’s Healthcare Move Turns Heads. We’re Buying These Pharma Stocks Instead.
According to a report in the Wall Street Journal, Costco ($COST) is about to launch its own Medicare Advantage plan in two states as part of a limi...
Amylyx Shares Jump 45% Following Positive Phase 3 Trial Results for GLP-1 Blocker Avexitide
Amylyx Pharmaceuticals ($AMLX) stock jumped 45% to $28.38 in early trading on Tuesday, August 18, after the company reported positive results from ...
Amylyx (AMLX) Climbs to Fresh High as Avexitide Moves Closer to Commercialization
Amylyx Pharmaceuticals Inc.
Is Amylyx Pharmaceuticals, Inc. (AMLX) Stock Ready for a Breakout Ahead of Key LUCIDITY Trial Data?
We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now. Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) is one of the best low-priced pharma stocks on this list.
12 Best Low-Priced Pharma Stocks to Buy Right Now
In this article, we will be taking a look at the 12 Best Low-Priced Pharma Stocks to Buy Right Now.
Amylyx Pharmaceuticals, Inc. (AMLX) Reports Q1 2026 Results and Pipeline Progress
We recently compiled a list of the 8 Best Small Cap Pharma Stocks to Buy Right Now. Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) is among the best pharmaceutical stocks.
8 Best Small Cap Pharma Stocks to Buy Right Now
In this article, we will be taking a look at the 8 Best Small Cap Pharma Stocks to Buy Right Now.
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q1 2026 Earnings Call Transcript
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q1 2026 Earnings Call Transcript May 7, 2026Amylyx Pharmaceuticals, Inc. misses on earnings expectations.
7 Best Small-Cap Drug Manufacturing Stocks to Buy According to Hedge Funds
In this article, we will take a look at some of the small-cap drug manufacturing stocks that are highly favored by hedge funds.
Hedge Fund Resource Center